Protocol and statistical analysis plan for a randomized controlled trial of the effect of intravenous iron on anemia in Malawian pregnant women in their third trimester (REVAMP – TT)
Gates Open Research · 2023
DOI: 10.12688/gatesopenres.14710.2 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Gates Open Research, 2023. Verfasst von Rebecca Harding und 15 weiteren Autor:innen. Beteiligte Einrichtung: Population Health and Immunity, Walter and Eliza Hall Institute of Medical Research, Parkville, Vic, 3052, Australia. Hauptthemen laut MEDLINE: Anemia, Iron-Deficiency, Anemia, Ferric Compounds. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gates Foundation, Bill and Melinda Gates Foundation.
Abstract (Originalsprache)
Background
Anemia affects 40% of pregnant women globally, leading to maternal mortality, premature birth, low birth weight, and poor baby development. Iron deficiency causes over 40% of anemia cases in Africa. Oral iron supplementation is insufficient for Low-and-Middle-Income-Countries (LMICs) to meet current WHO targets. We hypothesized that a single intravenous dose of Ferric Carboxymaltose (FCM) may be more effective than oral iron treatment for anemia recovery, particularly in these settings where women present late for antenatal care.
Methods
This is a two-arm parallel open-label individual-randomized controlled trial in third trimester, in malaria Rapid Diagnostic Test-negative pregnant women with moderate or severe anemia - capillary hemoglobin
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Population Health and Immunity, Walter and Eliza Hall Institute of Medical Research, Parkville, Vic, 3052, Australia.
- Training and Research Unit of Excellence (TRUE), 1 Kufa Road, P.O. Box 30538, Chichiri, Blantyre, BT3, Malawi.
- Department of Public Health, Kamuzu University of Health Sciences, School of Global and Public Health, Private Bag 360, Chichiri, Blantyre, BT3, Malawi.
- Infectious Diseases, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, 3000, Australia.
- Meander Medical Center, Laboratory for Clinical Chemistry, Maatweg 3, Amersfoort, 3813 TZ, The Netherlands.
- Centre for Reproductive Health, Kamuzu University of Health Sciences, Private Bag 360, Chichiri, Blantyre, BT3, Malawi.
ORCID-Profile: Rebecca Harding, Ricardo Ataíde, Zinenani Truwah, Glory Mzembe, William Stones, Katherine Johnson, Stefan Bode, Martin N Mwangi, Sabine Braat
Förderung
- Gates Foundation
- Bill and Melinda Gates Foundation
Zitieren
APA
Harding, R., Moya, E., Ataíde, R., Truwah, Z., Mzembe, G., Mhango, G., Demir, A. V., Stones, W., Randall, L., Seal, M., Johnson, K., Bode, S., Mwangi, M. N., Pasricha, S. R., Braat, S., & Phiri, K. S. (2023). Protocol and statistical analysis plan for a randomized controlled trial of the effect of intravenous iron on anemia in Malawian pregnant women in their third trimester (REVAMP – TT). Gates Open Research. https://doi.org/10.12688/gatesopenres.14710.2
Vancouver
Harding R, Moya E, Ataíde R, Truwah Z, Mzembe G, Mhango G, et al. Protocol and statistical analysis plan for a randomized controlled trial of the effect of intravenous iron on anemia in Malawian pregnant women in their third trimester (REVAMP – TT). Gates Open Research. 2023. doi:10.12688/gatesopenres.14710.2
BibTeX
@article{Harding2023,
author = {Harding, Rebecca and Moya, Ernest and Ataíde, Ricardo and Truwah, Zinenani and Mzembe, Glory and Mhango, Gomezgani and Demir, Ayşe V and Stones, William and Randall, Louise and Seal, Marc and Johnson, Katherine and Bode, Stefan and Mwangi, Martin N and Pasricha, Sant-Rayn and Braat, Sabine and Phiri, Kamija S},
title = {Protocol and statistical analysis plan for a randomized controlled trial of the effect of intravenous iron on anemia in Malawian pregnant women in their third trimester (REVAMP – TT)},
journal = {Gates Open Research},
year = {2023},
doi = {10.12688/gatesopenres.14710.2}
}
EUVIMED